ANIP
ANI Pharmaceuticals Inc.
$96.79
-$0.69(-0.71%)
37
Overall
--
Value
20
Tech
55
Quality
Market Cap
$2.10B
Volume
346.25K
52W Range
$52.50 - $99.50
Target Price
$99.00
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $76.3M | $128.6M | $176.8M | $201.6M | $206.5M | $208.5M | $216.1M | $316.4M | $486.8M | $614.4M | ||
| Total Revenue | $76.3M | $128.6M | $176.8M | $201.6M | $206.5M | $208.5M | $216.1M | $316.4M | $486.8M | $614.4M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $12.7M | $48.8M | $79.0M | $73.0M | $63.2M | $87.2M | $100.6M | $138.8M | $241.3M | $317.9M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $63.6M | $79.8M | $97.8M | $128.6M | $143.4M | $121.3M | $115.5M | $177.6M | $245.5M | $296.4M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $30.9M | $53.1M | $68.6M | $93.2M | $127.0M | $114.4M | $143.7M | $204.0M | $194.7M | $305.1M | ||
| Research & Development | $2.9M | $2.9M | $9.1M | $15.4M | $19.8M | $16.0M | $11.4M | $22.3M | $34.3M | $44.6M | ||
| Research Expense | -- | -- | -- | -- | -- | $16.0M | $11.4M | $22.3M | $34.3M | $44.6M | ||
| Selling, General & Administrative | $21.2M | $27.8M | $31.6M | $44.1M | $55.8M | $65.0M | $84.3M | $124.0M | $161.7M | $249.6M | ||
| Selling & Marketing Expenses | -- | -- | -- | -- | -- | $65.0M | $84.3M | $124.0M | $161.7M | $249.6M | ||
| Depreciation & Amortization | $6.9M | $22.3M | $27.9M | $33.7M | $44.6M | $44.6M | $47.3M | $57.0M | -- | -- | ||
| Depreciation & Amortization | $6.9M | $22.3M | $27.9M | $33.7M | $44.6M | $44.6M | $47.3M | $57.0M | -- | -- | ||
| Amortization | -- | -- | -- | -- | -- | $44.6M | -- | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | -- | $6.7M | $-11.3M | $780.0K | $670.0K | $-1.3M | $10.9M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $32.7M | $26.8M | $29.2M | $35.4M | $16.4M | $7.0M | $-28.2M | $-26.4M | $50.8M | $-8.7M | ||
| EBITDA | $39.6M | $42.3M | $56.3M | $68.6M | $60.7M | $28.1M | $3.1M | $23.7M | $110.5M | $80.4M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $11.0M | $11.3M | $12.0M | $14.8M | $13.0M | $9.5M | $11.9M | $28.1M | $26.9M | $17.6M | ||
| Net Non-Operating Interest Income/Expense | $11.0M | $11.3M | $12.0M | $14.8M | $13.0M | $9.5M | $11.9M | $-28.1M | $-26.9M | $-17.6M | ||
| Other Income/Expense | $41.0K | $-6.8M | $-848.0K | $-550.0K | $-303.0K | $-940.0K | $-16.0M | $3.9M | $-1.1M | $-7.7M | ||
| Other Special Charges | -- | -- | -- | -- | -- | $-11.8M | $-4.3M | $670.0K | $1.1M | $3.7M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | -- | -- | $500.0K | $5.7M | $1.1M | -- | ||
| Special Income Charges | -- | $6.7M | $903.0K | -- | $75.0K | $446.0K | $11.6M | $-5.7M | $-1.1M | -- | ||
| Impairment of Capital Assets | -- | $6.7M | $903.0K | -- | $75.0K | $446.0K | $2.4M | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $32.7M | $20.0M | $28.4M | $34.8M | $16.1M | $-16.5M | $-44.1M | $-36.0M | $50.8M | $-920.0K | ||
| Pre-Tax Income | $21.7M | $8.7M | $16.3M | $20.1M | $3.2M | $-26.0M | $-56.1M | $-64.0M | $23.8M | $-18.5M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $6.4M | $4.7M | $17.4M | $4.6M | $-2.9M | $-3.4M | $-13.5M | $14.8M | -- | -- | ||
| NET INCOME | ||||||||||||
| Net Income | $15.4M | $3.9M | $-1.1M | $15.5M | $6.1M | $-22.5M | $-42.6M | $-80.4M | $23.8M | $-18.5M | ||
| Net Income (Continuing Operations) | $15.4M | $3.9M | $-1.1M | $15.5M | $6.1M | $-22.5M | $-42.6M | $-78.8M | $23.8M | $-18.5M | ||
| Net Income (Discontinued Operations) | $15.4M | $3.9M | $-1.1M | $15.5M | $6.1M | $-22.5M | $-42.6M | $-80.4M | $23.8M | $-18.5M | ||
| Net Income (Common Stockholders) | $15.3M | $3.9M | $-1.1M | $15.3M | $6.0M | $-22.5M | $-42.8M | $-80.4M | $22.2M | $-20.1M | ||
| Normalized Income | $16.0M | $13.1M | $12.9M | $14.7M | $295.0K | $-28.9M | $-57.9M | $-41.3M | $18.6M | $-16.1M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-43.6M | $-101.9M | $-147.6M | $-166.2M | $-190.1M | $-201.5M | $-244.3M | -- | $436.0M | $623.0M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $11.4M | $11.4M | $11.5M | $11.7M | $11.8M | $12.0M | $12.6M | $16.3M | $18.0M | $19.3M | ||
| Average Shares Outstanding (Diluted) | $11.6M | $11.6M | $11.5M | $11.8M | $12.0M | $12.0M | $12.6M | $16.3M | $18.2M | $19.3M | ||
| Shares Outstanding | $11.5M | $11.6M | $11.7M | $11.9M | $12.1M | $12.3M | $16.7M | $12.7M | $21.7M | $21.7M | ||
| Basic EPS | $1.34 | $0.34 | $-0.09 | $1.31 | $0.51 | $-1.88 | $-3.4 | $-3.05 | $0.86 | $-1.04 | ||
| Basic EPS (Continuing Operations) | $1.34 | $0.34 | $-0.09 | $1.31 | $0.51 | $-1.88 | $-3.4 | $-3.05 | $0.86 | $-1.04 | ||
| Diluted EPS | $1.32 | $0.34 | $-0.09 | $1.3 | $0.50 | $-1.88 | $-3.4 | $-3.05 | $0.85 | $-1.04 | ||
| Diluted EPS (Continuing Operations) | $1.32 | $0.34 | $-0.09 | $1.3 | $0.50 | $-1.88 | $-3.4 | $-3.05 | $0.85 | $-1.04 | ||
| Dividend Per Share | -- | -- | -- | -- | -- | -- | $7.6 | -- | -- | -- | ||
| OTHER METRICS | ||||||||||||
| Accrued Preferred Stock Dividends | -- | -- | -- | -- | -- | -- | $190.0K | -- | -- | $1.6M | ||
| Gain On Sale Of P P E | -- | -- | -- | -- | -- | -- | -- | -- | -- | $5.3M | ||
| Minority Interests | -- | -- | -- | -- | -- | -- | -- | $-1.6M | -- | -- | ||
| Other Costof Revenue | -- | -- | -- | -- | -- | -- | -- | $138.8M | $181.5M | $250.2M | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | $446.0K | $2.4M | $112.0K | $112.0K | $7.6M | ||
| Otherunder Preferred Stock Dividend | -- | -- | -- | -- | -- | -- | $190.0K | $1.6M | $1.6M | $1.6M | ||
| Preferred Stock Dividends | -- | -- | -- | -- | -- | -- | $190.0K | $1.6M | $1.6M | $1.6M | ||
| Othspecchg | -- | -- | -- | -- | -- | -- | $8.8M | -- | -- | -- | ||
| Restruct | -- | -- | -- | -- | -- | -- | $500.0K | $5.7M | $1.1M | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ANIP | $96.79 | -0.7% | 346.25K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get ANI Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW